Clinical Trials Browser

NETWORK × Has results × Erlotinib Hydrochloride × Clear all

NCT02154490 2023-06-01

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

1,864 enrolled 12 charts

Recurrent Squamous Cell Lung Carcinoma

NCT01562028 2022-08-24

BELIEF

Phase 2 Completed

109 enrolled 20 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00436332 2020-04-02

S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma

Phase 2 Completed

84 enrolled 15 charts

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02926638 2020-03-19

Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches

Phase 2/3 Terminated

9 enrolled 5 charts

MET Positive

NCT00445848 2020-03-05

S0636: Erlotinib and Bevacizumab in Never-Smokers With Stage IIIB or Stage IV Primary Non-Small Cell Lung Cancer

Phase 2 Completed

89 enrolled 11 charts

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00661193 2020-02-20

S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 2 Completed

59 enrolled 13 charts

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00068367 2017-11-06

S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor

Phase 2 Completed

24 enrolled 7 charts

Sarcoma, Neurofibrosarcoma